Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860923 | 0.86 | BACE1 (0.41) | CLK4DYRK1BFYN | |
| SCHEMBL860924 | 0.86 | BACE1 (0.41) | CLK4DYRK1BFYN | |
| SCHEMBL20575885 | 0.85 | REN (0.31) | — | |
| SCHEMBL861249 | 0.85 | CLK4 (0.44) | CLK4DYRK1BFYNTYRO3NTRK2 | |
| SCHEMBL861248 | 0.85 | CLK4 (0.44) | CLK4DYRK1BFYNTYRO3NTRK2 | |
| SCHEMBL1806322 | 0.84 | PTK2 (0.38) | CLK4DYRK1BFYNTYRO3NTRK2 | |
| SCHEMBL1806325 | 0.84 | PTK2 (0.38) | CLK4DYRK1BFYNTYRO3NTRK2 | |
| SCHEMBL860444 | 0.83 | CLK4 (0.50) | CLK4DYRK1BFYNTYRO3NTRK2 | |
| SCHEMBL860443 | 0.83 | CLK4 (0.50) | CLK4DYRK1BFYNTYRO3NTRK2 | |
| SCHEMBL861046 | 0.82 | PARP10 (0.44) | CLK4DYRK1BFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-12-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CLK4 3097/4885DYRK1B 991/4885FYN 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.